Clinical-stage gene therapy company Genprex Inc (NASDAQ: GNPX) announced on Monday that positive preclinical data on its lead candidate, Reqorsa Gene Therapy, will be presented at the 2024 EORTC-NCI-AACR Symposium, taking place from 23-25 October 2024 in Barcelona.

The data focuses on Reqorsa's potential as a treatment for Ras inhibitor-resistant lung cancer, mesothelioma and glioblastoma.

Collaborators, including the University of Texas MD Anderson Cancer Center and New York University Langone Health, will showcase studies demonstrating that Reqorsa's TUSC2 gene therapy overcomes resistance in KRAS mutant lung cancer and suppresses tumour growth in mesothelioma and glioblastoma. Two provisional patent applications have been filed based on these findings.

Reqorsa, which uses Genprex's Oncoprex Delivery System, specifically targets cancer cells with the TUSC2 gene, delivering promising preclinical results.